Recent advances in the management of systemic lupus erythematosus (Q64044243)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026918%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

title

Recent advances in the management of systemic lupus erythematosus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026918%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

0 references

1 reference

systemic lupus erythematosus

1 reference

inferred from title

author

Maria Laura Bertolaccini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026918%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

author name string

Savino Sciascia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026918%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Massimo Radin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026918%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Dario Roccatello

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026918%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Giovanni Sanna

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026918%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

language of work or name

English

0 references

publication date

29 June 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026918%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026918%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026918%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

13 April 2020

page(s)

970

0 references

copyright license

start time

29 June 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The human U1-70K snRNP protein: cDNA cloning, chromosomal localization, expression, alternative splicing and RNA-binding

1 reference

12 December 2020

Clinical significance of antibodies to double stranded DNA (dsDNA) for systemic lupus erythematosus (SLE).

1 reference

12 December 2020

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

1 reference

12 December 2020

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

1 reference

12 December 2020

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

1 reference

12 December 2020

Treatment of systemic lupus erythematosus with LJP 394.

1 reference

12 December 2020

Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity

1 reference

12 December 2020

Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome.

1 reference

12 December 2020

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

1 reference

12 December 2020

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

1 reference

12 December 2020

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

1 reference

12 December 2020

Peptide-based immunotherapy of systemic lupus erythematosus

1 reference

12 December 2020

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Jak3 and the pathogenesis of severe combined immunodeficiency

1 reference

12 December 2020

CTLA4Ig: a novel inhibitor of costimulation

1 reference

12 December 2020

The role of BAFF in immune function and implications for autoimmunity

1 reference

12 December 2020

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

12 December 2020

The role of APRIL and BAFF in lymphocyte activation

1 reference

12 December 2020

B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells

1 reference

12 December 2020

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

12 December 2020

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

12 December 2020

LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus

1 reference

12 December 2020

A novel sphingosine-1-phosphate receptor agonist KRP-203 attenuates rat autoimmune myocarditis

1 reference

12 December 2020

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

1 reference

12 December 2020

Systemic lupus erythematosus.

1 reference

12 December 2020

Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept

1 reference

12 December 2020

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

1 reference

12 December 2020

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

1 reference

12 December 2020

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

1 reference

12 December 2020

Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist

1 reference

12 December 2020

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial

1 reference

12 December 2020

Sphingosine 1-phosphate receptor signaling

1 reference

12 December 2020

IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model

1 reference

12 December 2020

Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression

1 reference

12 December 2020

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

1 reference

12 December 2020

Abetimus sodium: a medication for the prevention of lupus nephritis flares

1 reference

12 December 2020

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases

1 reference

12 December 2020

Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis

1 reference

12 December 2020

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

1 reference

12 December 2020

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

1 reference

12 December 2020

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

1 reference

12 December 2020

Interferon-alpha: a therapeutic target in systemic lupus erythematosus

1 reference

12 December 2020

Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis

1 reference

12 December 2020

Overview of the biology of type I interferons

1 reference

12 December 2020

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Anti-TNF-alpha therapies in systemic lupus erythematosus

1 reference

12 December 2020

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

12 December 2020

Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy

1 reference

12 December 2020

The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus

1 reference

12 December 2020

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

1 reference

12 December 2020

The Dysregulation of Cytokine Networks in Systemic Lupus Erythematosus

1 reference

12 December 2020

Regulation of Mammalian Physiology, Development, and Disease by the Sphingosine 1-Phosphate and Lysophosphatidic Acid Receptors

1 reference

12 December 2020

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

12 December 2020

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

1 reference

12 December 2020

A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease

1 reference

12 December 2020

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

1 reference

12 December 2020

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

1 reference

12 December 2020

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

1 reference

12 December 2020

Type I interferons as biomarkers in autoimmune diseases

1 reference

12 December 2020

Meryl Streep and the problems of clinical trials

1 reference

12 December 2020

BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus.

1 reference

12 December 2020

Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes

1 reference

12 December 2020

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

1 reference

12 December 2020

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

12 December 2020

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

12 December 2020

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

1 reference

12 December 2020

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.

1 reference

12 December 2020

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

1 reference

12 December 2020

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

1 reference

12 December 2020

B-cell-targeted therapies in systemic lupus erythematosus

1 reference

12 December 2020

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

1 reference

12 December 2020

Epratuzumab for systemic lupus erythematosus

1 reference

12 December 2020

Belimumab for systemic lupus erythematosus

1 reference

12 December 2020

Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity

1 reference

12 December 2020

The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity

1 reference

12 December 2020

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

1 reference

12 December 2020

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study

1 reference

12 December 2020

Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.

1 reference

12 December 2020

Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment

1 reference

12 December 2020

Targeting TNF-α for the treatment of inflammatory bowel disease

1 reference

12 December 2020

TNF-alpha inhibitors in Systemic Lupus Erythematosus. A case report and a systematic literature review

1 reference

12 December 2020

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006.

1 reference

12 December 2020

Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study

1 reference

12 December 2020

Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study

1 reference

12 December 2020

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

1 reference

12 December 2020

Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.

1 reference

12 December 2020

The pathology of T cells in systemic lupus erythematosus

1 reference

12 December 2020

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

1 reference

12 December 2020

Is there still a role for abatacept in the treatment of lupus?

1 reference

12 December 2020

Obinutuzumab: a new class of anti-CD20 monoclonal antibody.

1 reference

12 December 2020

Post-marketing experiences with belimumab in the treatment of SLE patients

1 reference

12 December 2020

The efficacy of novel B cell biologics as the future of SLE treatment: a review

1 reference

12 December 2020

Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.

1 reference

12 December 2020

Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies

1 reference

12 December 2020

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

1 reference

12 December 2020

T cells as a therapeutic target in SLE.

1 reference

12 December 2020

Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.

1 reference

12 December 2020

A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment

1 reference

12 December 2020

B-cell survival factors in autoimmune rheumatic disorders

1 reference

12 December 2020

Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.

1 reference

12 December 2020

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controll

1 reference

12 December 2020

Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study

1 reference

12 December 2020

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

1 reference

12 December 2020

Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices

1 reference

12 December 2020

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA.

1 reference

12 December 2020

Shaping the spectrum - From autoinflammation to autoimmunity.

1 reference

12 December 2020

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

1 reference

12 December 2020

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

1 reference

12 December 2020

1 reference

12 December 2020

Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy

1 reference

12 December 2020

Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus

1 reference

12 December 2020

Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review

1 reference

12 December 2020

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register

1 reference

12 December 2020

SLE-Associated Defects Promote Altered T Cell Function

1 reference

12 December 2020

10.12688/F1000RESEARCH.13941.1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026918%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026918%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

PubMed publication ID

30026918

1 reference